Back to Journals » Biologics: Targets and Therapy » Volume 2 » Issue 4

Anticomplement therapy

Authors Kulkarni PA, Afshar-Kharghan V

Published 5 December 2008 Volume 2008:2(4) Pages 671—685

DOI https://doi.org/10.2147/BTT.S2753

Prathit A Kulkarni1, Vahid Afshar-Kharghan2

1Baylor College of Medicine, Houston, Texas, USA; 2The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA

Abstract: The complement system is an important part of innate immunity; however, as with other parts of the immune system, the complement system can become pathologically activated and create or worsen disease. Anticomplement reagents have been studied for several years, but only recently have they emerged as a viable therapeutic tool. Here, we describe the role of the complement system in a wide array of diseases, as well as the use of anticomplement therapy as treatment for these diseases in animal models and in human clinical trials. Specifically, we will discuss the role of anticomplement therapy in paroxysmal nocturnal hemoglobinuria, glomerulonephritis, and heart disease, including coronary artery disease, myocardial infarction, and coronary revascularization procedures such as percutaneous coronary angioplasty and coronary artery bypass graft surgery.

Keywords: complement, paroxysmal nocturnal hemoglobinuria, glomerulonephritis, myocardial infarction, cardiopulmonary bypass

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]